Intrapatient Variation in Response to Systemic Therapy in Advanced Hepatocellular Carcinoma

The evidence presented here suggests that caution should be exercised in the application of progression-based metrics such as PFS as an end point in HCC clinical trials. Ultimately, there was consistently a considerable proportion of patients who were classified as having lesions within their liver which had a divergent response to treatment.